Can acute exacerbations of asthma be prevented with a four-fold increase in inhaled corticosteroid dose?

Submission date 28/09/2005	Recruitment status No longer recruiting	[] Prospectively registered	
		[_] Protocol	
Registration date	Overall study status	[] Statistical analysis plan	
21/11/2005	Completed	[X] Results	
Last Edited 13/07/2009	Condition category Respiratory	Individual participant dat	

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s) Scientific

Contact name Dr Timothy Harrison

Contact details

Department Respiratory Medicine Nottingham City Hospital NHS Trust Hucknall Road Nottingham United Kingdom NG5 1PB

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers 03/082

- а

Study information

Scientific Title

Study objectives

That acute exacerbations of asthma requiring oral corticosteroids can be prevented with preemptive treatment with a four-fold increase in the dose of inhaled corticosteroid.

Ethics approval required Old ethics approval format

Ethics approval(s) Not provided at time of registration

Study design Randomised controlled trial

Primary study design Interventional

Secondary study design Randomised controlled trial

Study setting(s) Not specified

Study type(s) Prevention

Participant information sheet

Health condition(s) or problem(s) studied Asthma

Interventions

Comparison of the effect of increasing regular inhaled corticosteroid four-fold to continuing on same dose in the event of increasing asthma symptoms.

Intervention Type Drug

Phase Not Specified

Drug/device/biological/vaccine name(s) Corticosteroids

Primary outcome measure

The primary outcome will be the number of exacerbations requiring oral steroids in the active group compared with the placebo group.

Secondary outcome measures

The total number of exacerbations and days with peak flow less than 15% baseline will also be compared. The sensitivity and specificity of our criteria to detect an exacerbation requiring prednisolone will be determined. The total dose of inhaled and oral corticosteroids used by both groups will be calculated.

Overall study start date 01/04/2004

Completion date

30/09/2006

Eligibility

Key inclusion criteria

- 1. Written Informed consent prior to participation in the trial
- 2. Male or female patients 16 years of age or older
- 3. Documented diagnosis of asthma
- 4. Treatment with 200 to 1000 mcg inhaled beclomethasone dipropionate or equivalent

5. At least one exacerbation requiring a temporary increase in inhaled corticosteroid or oral corticosteroids in the preceding 12 months

6. No oral corticosteroids for 4 weeks prior to or during the run-in period

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants 500

Key exclusion criteria

- 1. Other respiratory diagnosis or relevant medical condition
- 2. Smoking history of greater than 20 pack years

3. Subjects already using a management plan to deal with exacerbations and who would not wish to be randomised to placebo

4. Pregnant or nursing women

Date of first enrolment

01/04/2004

Date of final enrolment

30/09/2006

Locations

Countries of recruitment England

United Kingdom

Study participating centre Department Respiratory Medicine Nottingham United Kingdom NG5 1PB

Sponsor information

Organisation Nottingham City Hospital NHS Trust (UK)

Sponsor details Hucknall Road Nottingham England United Kingdom NG5 1PB +44 (0)115 9691169 gdochert@ncht.trent.nhs.uk

Sponsor type Hospital/treatment centre

ROR https://ror.org/05y3qh794

Funder(s)

Funder type Charity

Funder Name Asthma UK (UK), ID 03/082

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/10/2009		Yes	No